Business · 1 sources covering this

Higher costs drag Zydus Lifesciences' Q1 profit down 36%; revenue rises 22%

Revenue from operations rose 22 per cent to Rs 8,017 crore, led by India formulations, consumer wellness and international markets, while EBITDA margin contracted

Share:WhatsApp X Reddit Facebook LinkedIn

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

Business StandardCenter·3h ago
Higher costs drag Zydus Lifesciences' Q1 profit down 36%; revenue rises 22%
Revenue from operations rose 22 per cent to Rs 8,017 crore, led by India formulations, consumer wellness and international markets, while EBITDA margin contracted
Read at Business Standard →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://hindustansphere.com/embed/cluster/2c0c67541a704d6fd6b84db3926e4f0a85347385"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Higher costs drag Zydus Lifesciences' Q1 profit down 36%; revenue rises 22%"></iframe>

Higher costs drag Zydus Lifesciences' Q1 profit down 36%; revenue rises 22%

How 1 sources are covering this

Higher costs drag Zydus Lifesciences' Q1 profit down 36%; revenue rises 22%

More from Business

Shivaji Maharaj Statue Targeted In Pune: Woman Allegedly Throws Slipper, Stones; Locals Confront Her

US Stock Market Today: Dow Rises As Wall Street Shrugs Off Oil Fears; Nasdaq In Red Despite Nvidia Surge

Mutual fund investors rejig portfolios, favour select debt funds over equities in July 2026

Mirzapur: The Movie Official Trailer Releases: Kaleen Bhaiya's Power-Packed Dialogue Steals The Show

Reader

Trust & legal

Across the network